LumiraDx (LMDX) Stock Price, News & Analysis

Company Overview

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.0076 to $0.0160
• 52-Week Range: N/A
• Volume: 132.24 million shs
• Average Volume: 56.75 million shs
• Market Capitalization: $5.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LMDX Stock Analysis - Frequently Asked Questions

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) announced its earnings results on Thursday, August, 24th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. The firm earned $21 million during the quarter, compared to analyst estimates of $21.07 million.

What other stocks do shareholders of LumiraDx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LumiraDx investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), Abbott Laboratories (ABT), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Wayfair (W).

Company Calendar

• Last Earnings: 8/24/2023
• Today: 6/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LMDX
• CIK: 1685428
• Web: www.lumiradx.com
• Phone: 354-640-0540
• Fax: N/A
• Employees: 1,210
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$447.79 million
• Net Margins: -268.45%
• Pretax Margin: -264.58%
• Return on Equity: N/A
• Return on Assets: -77.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.45
• Quick Ratio: 0.23

Sales & Book Value

• Annual Sales: $126.52 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.33) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 318,546,000
• Free Float: 205,749,000
• Market Cap: $5.10 million
• Optionable: Not Optionable
• Beta: 1.73